- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00961194
Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain (KETACLUD)
Evaluation of the Analgesic Effect of Orally Administrated Ketamine in Peripheral Neuropathic Pain Disease: Comparison of Three Doses Versus Placebo.
Nowadays, available drugs cannot always produce pain relief in patients with neuropathic pain disease.
It is believed that drugs acting as antagonists of the N-methyl-D-aspartic acid (NMDA) receptor may have been efficient in the treatment of neuropathic pain disorders.
Ketamine is the only NMDA receptor antagonist commercially available in France. Ketamine is usually administered intravenously for surgical anesthesia.
The intravenous administration of ketamine will be difficult to manage in the treatment of chronic neuropathic pain.
Some trials using oral ketamine for the treatment of neuropathic pain were conducted but results were heterogeneous. This may be explained by the different range of ketamine doses tested.
The aim of this clinical trial is to identify a safe and an efficient dose of orally administrated ketamine for the treatment of peripheral neuropathic pain.
The clinical trial will be conducted in Toulouse Hospital, France. This study is a randomized, double-blind, placebo-controlled trial. The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).
연구 개요
상세 설명
In previous studies, it was shown that when ketamine was administrated by the intravenous route, its analgesic action was rapid. In one study, when oral ketamine was administrated to patients suffering from neuropathic pain, in six out of nine patients, pain was relieved after 24 hours post-administration.
In this study, ketamine will be administrated during seven days, which will allow us to evaluate ketamine efficiency and safety.
The effect of ketamine on pain intensity will be mainly studied using a visual analogue scale (VAS) but also taking into account the score assigned by the patient to his pain. This score will be noted down by patients before, during and after ketamine treatment.
Evaluation of benefit/risk for ketamine administration during this trial, shows that even if adverse events are not excluded, the benefit for the patients may be neuropathic pain relief.
Because clinical current knowledge regarding oral administration of ketamine is limited, this trial intends to enlarge information about ketamine efficiency and safety, more particularly in neuropathic pain disorders.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Toulouse, 프랑스, 31059
- Service de Neurochirurgie
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients must suffer from peripheral neuropathic chronic pain.
- Pain score must be at least 40 mm in a VAS (reflecting pain intensity during the 7 days and the day before visit 1).
- Patients in which pain is not satisfactory relieved by level 1, 2 or 3 analgesic drugs (associated or not with antidepressants or antiepileptic drugs). Patients treated with level 2 or 3 analgesic drugs must stop these treatments one week before and during ketamine treatment.
- Patients must benefit from the French Social security system.
- Patients must be able to complete the tests.
- Patients must give a written informed consent.
- Patients must be aged from 30 to 90 years.
- Female fertile patients must use an efficient method of contraception.
Exclusion Criteria:
- Patients not suffering from peripheral neuropathic chronic pain.
- Pain score is less than 40 mm in a VAS (reflecting pain intensity during the 7 days and the day before visit 1).
- Patients not able to complete the tests.
- Patients not able to stop level 2 or 3 analgesic drugs.
Patients in which ketamine is contraindicated:
- Hypersensibility to one of the compounds of the ketamine syrup
- Uncontrolled arterial hypertension
- Recent cardio vascular accident
- Severe cardiac problems
- Drug abuse
- Psychosis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: placebo
The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3). The oral ketamine will be administered in form of syrup. |
Initial dosage: 250 mg/5 ml Three doses of ketamine will be tested:
The oral ketamine will be administered in form of syrup.
다른 이름들:
|
실험적: dose of ketamine tested = 0.35 mg/kg
The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3). The oral ketamine will be administered in form of syrup. |
Initial dosage: 250 mg/5 ml Three doses of ketamine will be tested:
The oral ketamine will be administered in form of syrup.
다른 이름들:
|
활성 비교기: dose of ketamine tested = 0.7 mg/kg
The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3). The oral ketamine will be administered in form of syrup. |
Initial dosage: 250 mg/5 ml Three doses of ketamine will be tested:
The oral ketamine will be administered in form of syrup.
다른 이름들:
|
활성 비교기: dose of ketamine tested = 1.4 mg/kg
The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3). The oral ketamine will be administered in form of syrup. |
Initial dosage: 250 mg/5 ml Three doses of ketamine will be tested:
The oral ketamine will be administered in form of syrup.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Evaluation of pain intensity using a 10 cm visual analogue scale (VAS) (0 = no pain; 10 = worst possible pain) before and after 7 days of oral administration of one of the three doses of ketamine or placebo.
기간: V1 (14 days before ketamine treatment), at V2 (before oral administration of one of the three doses of ketamine or placebo), at V3 (after 7 days of oral administration), and at V4 (after 7 days of the end of treatment)
|
V1 (14 days before ketamine treatment), at V2 (before oral administration of one of the three doses of ketamine or placebo), at V3 (after 7 days of oral administration), and at V4 (after 7 days of the end of treatment)
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Pain intensity will be evaluated by measuring thermal sensibility. A thermode will be used to determine the heat and cold pain thresholds (thermotest) and by measuring hyperalgesia
기간: Thermotest and hyperalgesia will be assessed at T0 and T1 hour, at visit 2 and visit 3
|
Thermotest and hyperalgesia will be assessed at T0 and T1 hour, at visit 2 and visit 3
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Nathalie Cantagrel, MD, University Hospital, Toulouse
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 0730102
- AOL 2007 (기타 식별자: AOL 2007)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Ketamine에 대한 임상 시험
-
Vance Thompson Vision알려지지 않은
-
Complexo Hospitalario Universitario de A Coruña완전한